Abstract Number: 1234 • 2013 ACR/ARHP Annual Meeting
Effects Of Biological Therapy In Bone Metabolism In Patients With Chronic Inflammatory Arthropathies
Background/Purpose: The efficacy of biological agents in the treatment of chronic inflammatory arthropathies is well known, however, the effect of this therapy in bone metabolism…Abstract Number: 863 • 2013 ACR/ARHP Annual Meeting
Romosozumab Administration Is Associated With Significant Improvements In Lumbar Spine and Hip Volumetric Bone Mineral Density and Content Compared With Teriparatide
Background/Purpose: Sclerostin is an osteocyte-derived inhibitor of osteoblast activity. Romosozumab, a monoclonal antibody to sclerostin stimulates bone formation and decreases bone resorption. In a phase…Abstract Number: 864 • 2013 ACR/ARHP Annual Meeting
Further Reduction In Nonvertebral Fracture Rate Is Observed Following 3 Years Of Denosumab Treatment: Results With Up To 7 Years In The Freedom Extension
Further Reduction in Nonvertebral Fracture Rate Is Observed Following 3 Years of Denosumab Treatment: Results With up to 7 Years in the FREEDOM ExtensionBackground/Purpose: Some…Abstract Number: 865 • 2013 ACR/ARHP Annual Meeting
Vertebral Fractures In The 3 Year Period Following Steroid Initiation Among Children With Chronic Illnesses
Background/Purpose: : To describe the pattern and frequency of incident vertebral fractures (VF) in glucocorticoid (GC)-treated children and to determine the clinical factors at baseline…Abstract Number: 373 • 2013 ACR/ARHP Annual Meeting
Menopause Occurs Earlier and Is An Independent Risk Factor For Osteoporosis In Women With Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) and early menopause (Abstract Number: 2262 • 2013 ACR/ARHP Annual Meeting
Antibody To Malondialdehyde-Acetaldehyde Adducts (MAA) Is a Biomarker Of Inflammation and Is Correlated With The Disease Activity In Rheumatoid Arthritis
Background/Purpose: Cardiovascular disease (CVD) is a major cause of morbidity and mortality in patients with rheumatoid arthritis (RA). While there are many markers used…Abstract Number: 1785 • 2013 ACR/ARHP Annual Meeting
Structural Determinants Of Low Vertebral Strength In Pediatric Systemic Lupus Erythematosus
Background/Purpose: Children with systemic lupus erythematosus (SLE) are at high risk for bone fragility. Studies in pediatric SLE using two-dimensional lumbar spine (LS) dual X-ray…Abstract Number: 1548 • 2013 ACR/ARHP Annual Meeting
Effect Of TNF Inhibitors On Bone Mineral Density In Patients With Ankylosing Spondylitis- a Systematic Review and Meta-Analysis
Background/Purpose: Patients with ankylosing spondylitis (AS) are susceptible to osteoporosis (OP) and have high fracture risk. Currently, no specific strategies are established to treat OP…Abstract Number: 1237 • 2013 ACR/ARHP Annual Meeting
Denosumab Leads To Significantly Greater Increases In Bone Mineral Density Than Ibandronate and Risedronate In Postmenopausal Women At High Risk For Fracture Who Were Previously Treated With An Oral Bisphosphonate
Denosumab Leads to Significantly Greater Increases in Bone Mineral Density Than Ibandronate and Risedronate in Postmenopausal Women at High Risk for Fracture Who Were Previously…Abstract Number: 1239 • 2013 ACR/ARHP Annual Meeting
The Effects Of Hyperparathyroidism On Body Mass Index and Bone Mineral Density- An Observational Case-Control Study
Background/Purpose: Hyperparathyroidism is associated with reduced bone mineral density (BMD) and increased fracture risk. A previous study from this group has shown that bone loss…Abstract Number: 1222 • 2013 ACR/ARHP Annual Meeting
Analysis Of Corelation Of Bone Mineral Density Of Spine With Other Sites In Ankylosing Spondylitis As Compared To Rheumatoid Arthritis and Control Populations
Background/Purpose: Bone mineral density (BMD) at the 3 central sites usually correlates with each other but the effect of disease states on this correlation is…Abstract Number: 1230 • 2013 ACR/ARHP Annual Meeting
Analysis Of Fracture Risk Assessment Score (FRAX) Correlation With Bone Mineral Density (BMD) In Males and Post-Menopausal Females
Background/Purpose: Fracture Risk Assessment Tool (FRAX) is a useful clinical tool for assessment of fracture risk and a major development in evaluation of osteoporosis. Its…Abstract Number: 1970 • 2012 ACR/ARHP Annual Meeting
Utility of Spine Bone Mineral Density in Fracture Prediction within the Fracture Risk Assessment Tool (FRAX)
Background/Purpose: Predicting which individuals are at risk to experience a fracture and modify that risk is important in preventative health. The WHO’s Fracture Risk Assesment…Abstract Number: 1958 • 2012 ACR/ARHP Annual Meeting
Bone Mineral Density in Lupus Erythematosus Women One Year After Rituximab Therapy
Background/Purpose: Low bone mineral density (BMD) and osteoporosis may be significant complications in patients with systemic lupus erythematosus (SLE). Recent studies have shown that biologic therapy could…Abstract Number: 1557 • 2012 ACR/ARHP Annual Meeting
What Percentage of Postmenopausal Women Younger Than Age 65 Years Have Low Bone Mineral Density At a Family Health Center?
Background/Purpose: Many younger women, < 65 years of age may have low bone mineral density (BMD) that remains undetected in clinical practice due to following…